Dr. Jim Tananbaum’s Career As A Successful Biotechnology Investor

Dr. Jim Tananbaum is an entrepreneur in the biotechnology industry. He holds a number of degrees, the first being his Bachelor’s Degree in Math and Computer Science. He graduated in 1989 from Harvard Medical School with his Doctor of Medicine and from MIT with his Master of Science in Information Theory. He is also a graduate of Harvard Business School, earning his MBA in 1991. His medical specialties include genetic epidemiology, clinical immunology, and clinical pharmacology.

It was in January 1991 that Dr. Jim Tananbaum started his professional career, co-founding GelTex. He served as both the Chief Executive Officer of this company, from the beginning of 1991 until the end of 1992, as well as a board member from January 1993 until January 1997. This company created non-systemic drugs and released two drugs with FDA approval, Renzela and Cholestagel. This company was acquired by Genzyme in 1997 for $1.6 billion.

In addition to serving on the board at GelTex, from 1993 to 1997 Dr. Tananbaum was a Partner at Sierra Ventures which was a healthcare services investment firm. Among the companies he invested in were CareSelect and Amerigroup. He left in 1997 in order to co-found Theravance which is a biopharmaceutical company with a diverse set of expertises.

In 2001, Dr. Tananbaum again co-founded a company in the biotechnology industry, Prospect Venture Partners, which was a venture capital firm that focused on investing in startup pharmaceutical companies. He was this company’s Managing Director and successfully led the company for 9 years.

Dr. Tananbaum founded Foresite Capital Management in 2010 and continues to lead the company as its CEO. This company, headquartered in San Francisco, invests in biotechnology firms with late-stage products. The type of companies he invests in includes those that make medical devices, healthcare services, genomics, diagnostics, and biotechnology. His wealth of experience and knowledge has led to him being a very effective investor including his being named to Inc. Magazines top 100 Investors Midas list for 2016.

See more: https://www.linkedin.com/in/jim-tananbaum-a7562a7/

Investment Strategy Tips

The infamous investor Warren Buffett announced a wager for $1 million in the name of charity. He is betting that he can do a better job of investing than an assortment of hedge fund managers through the S&P 500. The winner of the bet will be determined by the end of 2017.

Warren Buffett feels there are way too many expensive and mediocre investors working in a style that is shortchange. His ideas that low-cost investments should be simple by nature and thought of as long term investments is popular amongst many in the financial world. Buffett takes the approach of analyzing companies rigorously and creating portfolios that are durable. Over the decades, he has been rewarded immensely for his philosophy. There is no person in the world who has been an evangelist for retirement savings. He wants all people to get invested and stay invested.

Capital Group is headed by Timothy Armour who holds the title Chief Executive Officer. He also functions as an equity portfolio manager. For more than 34 years, he has worked in the world of investment. He has been a lifelong career man at Capital Group. It is an amazing success story that someone who started at the bottom of the company 3 decades ago managed to rise to its highest position. While working his way up as an analyst, Timothy focused on U.S. service companies and the telecommunications industry.

At the very beginning of his career, he was in The Associates Program. His talent was recognized early and he outpaced the other associates. Tim currently lives in Los Angeles, and he received his education at Middlebury College. He is a respected man within the local community of financial experts, and when he is not devoting his energy to running Capital Group, he is concerned with the welfare of others.

Learn more about Tim Armour: http://www.investmentnews.com/article/20150729/FREE/150729863/capital-group-parent-names-armour-chairman-replacing-rothenberg